Eur J Musculoskel Dis 2021 Sep-Dec;10(3):131-135
REVIEW
MYOFASCIAL PAIN SYNDROME: AN UNDERSTANDING OF MOLECULAR BIOLOGY AND MANAGEMENT
G. Carnevali1, F. Lodi2 and L. Zucchinelli3
1Private Practice, Ferrara, Italy;
2Private Practice, Ferrara, Italy;
3Private Practice, Bergamo, Italy
Correspondence to:
Dr Giulia Carnevali, MD, DDS
Maxillofacial Surgeon
Private practice,
Corso Porta Po 68,
Ferrara, Italy
e-mail: giulia.carnevali84@gmail.com
|
Received: 7 October 2021 Copyright: |
ISSN: 2038-4106 This publication and/or article is for individual use only and may not be further reproduced without written permission from the copyright holder. Unauthorized reproduction may result in financial and other penalties. Disclosure: All authors report no conflicts of interest relevant to this article. |
ABSTRACT
Myofascial Pain Syndrome (MPS) is widespread, undiagnosed, and carries a high cost. While people suffer for years, physicians frequently dismiss MPS. Although MPS can progress into fibromyalgia, there are currently no proven effective treatments for either condition. The subject of several investigations is central sensitisation. This scoping review’s objective is to thoroughly seek studies that address the molecular biology and clinical facets of myofascial pain syndrome. We conducted a thorough search of several keywords in Science Direct, PubMed, and Google Scholar to find studies from 2013 to 2021, based on title and abstract, followed by a complete text analysis. Guidelines for PRISMA-ScR review are followed. A better knowledge of the molecular and subcellular mechanisms underlying this condition can be beneficial in effectively managing MPS. This increased understanding might also help current treatment plans to be optimised.
KEYWORDS: pain, fascial tightness, trigger point, literature review
